Alder Biopharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alder Biopharmaceuticals, Inc.
The company reported $6.8bn in fourth quarter revenue, missing analyst consensus of $6.9bn even with revenue from supplying Lilly’s COVID-19 antibodies. Enbrel and Aimovig fell by double digits.
The market for novel preventive and acute treatments grew from three anti-CGRP antibodies at the start of 2020 to four biologics and two oral drugs against CGRP plus a small molecule 5-HT1F inhibitor.
Lundbeck adapted its launch strategy for its quarterly injectable migraine therapy Vyepti because of the COVID-19 pandemic, becoming more virtual, and payer responses have been encouraging.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
- H. Lundbeck A/S
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.